A prospective, randomized, open, multicentre phase III study to assess the efficacy of secondary adjuvant endocrine anastrozole therapy for 2 further yrs vs 5 further yrs in patients with HR +Ve breast cancer after 5-yr primary adjuvant endocrine therapy

Trial Profile

A prospective, randomized, open, multicentre phase III study to assess the efficacy of secondary adjuvant endocrine anastrozole therapy for 2 further yrs vs 5 further yrs in patients with HR +Ve breast cancer after 5-yr primary adjuvant endocrine therapy

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 07 Jul 2017

At a glance

  • Drugs Anastrozole (Primary)
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Acronyms SALSA
  • Sponsors AstraZeneca
  • Most Recent Events

    • 23 Sep 2015 Planned End Date changed from 1 Jan 2019 to 1 Dec 2020 as reported by ClinicalTrials.gov record.
    • 23 Sep 2015 Planned primary completion date changed from 1 Jan 2019 to 1 Dec 2020 as reported by ClinicalTrials.gov record.
    • 08 Dec 2010 Planned end date changed from 1 Jun 2020 to 1 Jan 2019 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top